195 related articles for article (PubMed ID: 31954833)
1. Faropenem resistance causes in vitro cross-resistance to carbapenems in ESBL-producing Escherichia coli.
Gandra S; Choi J; McElvania E; Green SJ; Harazin M; Thomson RB; Dantas G; Singh KS; Das S
Int J Antimicrob Agents; 2020 Mar; 55(3):105902. PubMed ID: 31954833
[TBL] [Abstract][Full Text] [Related]
2. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
3. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.
Tängdén T; Adler M; Cars O; Sandegren L; Löwdin E
J Antimicrob Chemother; 2013 Jun; 68(6):1319-26. PubMed ID: 23478794
[TBL] [Abstract][Full Text] [Related]
4. Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
Johnson JK; Robinson GL; Pineles LL; Ajao AO; Zhao L; Albrecht JS; Harris AD; Thom KA; Furuno JP
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167543
[TBL] [Abstract][Full Text] [Related]
5. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
6. Structural Alteration of OmpR as a Source of Ertapenem Resistance in a CTX-M-15-Producing Escherichia coli O25b:H4 Sequence Type 131 Clinical Isolate.
Dupont H; Choinier P; Roche D; Adiba S; Sookdeb M; Branger C; Denamur E; Mammeri H
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264855
[TBL] [Abstract][Full Text] [Related]
7. [In vitro emergence of ertapenem resistance in Escherichia coli producing extended-spectrum β-lactamase].
Villar HE; Jugo MB; Visser M; Hidalgo M; Hidalgo G; Maccallini GC
Rev Esp Quimioter; 2014 Mar; 27(1):51-5. PubMed ID: 24676243
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
Kiremitci A; Dinleyici EC; Erben N; Durmaz G; Yargic ZA; Aybey AD; Usluer G
Expert Opin Pharmacother; 2008 Jun; 9(9):1441-9. PubMed ID: 18518776
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
10. Underlying mechanisms of carbapenem resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases.
Baroud M; Dandache I; Araj GF; Wakim R; Kanj S; Kanafani Z; Khairallah M; Sabra A; Shehab M; Dbaibo G; Matar GM
Int J Antimicrob Agents; 2013 Jan; 41(1):75-9. PubMed ID: 23142087
[TBL] [Abstract][Full Text] [Related]
11. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms.
Mody RM; Erwin DP; Summers AM; Carrero HA; Selby EB; Ewell AJ; Moran KA
Ann Clin Microbiol Antimicrob; 2007 Jun; 6():6. PubMed ID: 17553151
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli.
Tärnberg M; Ostholm-Balkhed A; Monstein HJ; Hällgren A; Hanberger H; Nilsson LE
Eur J Clin Microbiol Infect Dis; 2011 Aug; 30(8):981-7. PubMed ID: 21298459
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. isolates in Mongolia.
Kao CY; Udval U; Huang YT; Wu HM; Huang AH; Bolormaa E; Yan JJ; Urangoo Z; Batbaatar G; Khosbayar T; Wu JJ
J Microbiol Immunol Infect; 2016 Oct; 49(5):692-700. PubMed ID: 26194952
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).
Hawser SP; Bouchillon SK; Lascols C; Hackel M; Hoban DJ; Badal RE; Cantón R
Clin Microbiol Infect; 2012 Mar; 18(3):253-9. PubMed ID: 21635662
[TBL] [Abstract][Full Text] [Related]
15. [Carbapenem resistance in ESBL positive Enterobacteriaceae isolates causing invasive infections].
Eser OK; Altun Uludağ H; Ergin A; Boral B; Sener B; Hasçelik G
Mikrobiyol Bul; 2014 Jan; 48(1):59-69. PubMed ID: 24506716
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
17. Nosocomial blood-stream infections from extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumonia from GB Pant Hospital, New Delhi.
Taneja J; Mishra B; Thakur A; Dogra V; Loomba P
J Infect Dev Ctries; 2010 Sep; 4(8):517-20. PubMed ID: 20818104
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
[TBL] [Abstract][Full Text] [Related]
19. Molecular Characterization of Carbapenemase-Nonproducing Clinical Isolates of Escherichia coli (from a Thai University Hospital) with Reduced Carbapenem Susceptibility.
Nuramrum S; Chanawong A; Lunha K; Lulitanond A; Sangka A; Wilailuckana C; Angkititrakul S; Charoensri N; Wonglakorn L; Chaimanee P; Chetchotisakd P
Jpn J Infect Dis; 2017 Nov; 70(6):628-634. PubMed ID: 28890516
[TBL] [Abstract][Full Text] [Related]
20. Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
Jean SS; Lee WS; Bai KJ; Yu KW; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):290-5. PubMed ID: 25600841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]